A large new study based on Medicaid data identifies a clear trend of people staying on their HIV medications longer than they used to.
In a small, randomized Phase I/II clinical trial (SAT1), researchers at University of California San Diego School of Medicine say a 100-year-old drug called suramin, originally developed to treat African sleeping sickness, was safely administered to children with autism spectrum disorder (ASD), who subsequently displayed measurable, but transient, improvement in core symptoms of autism.
Research published in the Journal of Clinical Investigation Insight shows that cellular stress in the brain may contribute to development of nonalcoholic fatty liver disease.
University of Leicester researchers design novel urine test to help to diagnose adherence to blood pressure medications.
Every day 12 Australian diabetics have a limb amputated because of a non-healing wound. Globally, it's one every 30 seconds. A molecule produced by a Thai liver parasite could be the solution to those non-healing wounds -- and scientists from the Australian Institute of Tropical Health and Medicine are now able to produce a version of the molecule on a large enough scale to make it available for laboratory tests and eventually clinical trials.
A team of University at Buffalo-led researchers found that combinations of three antibiotics -- that are each ineffective against superbugs when used alone -- are capable of eradicating two of the six ESKAPE pathogens when delivered together.
Researchers at the University of Michigan, Stanford University and biotech company ConfometRx have captured the first cryo-electron microscopy snapshots of a key cellular receptor in action.
Induced pluripotent stem cells (IPSCs) hold great promise in regenerative medicine, personalized medicine and drug discovery. However, while avoiding the ethical controversies associated with embryonic stem cells, they carry neoplastic risk owing to the use of the oncogenes c-Myc and Lin28. This has limited their utility in the biomedical arena.
A new study of malaria medicine quality in eight sub-Saharan African countries has found a large and potentially growing market for non-quality-assured (QA) malaria treatments -- medicines not pre-approved by global health organizations -- as much as 20 percent of the private-sector market in Kenya, and 42 percent in the Democratic Republic of Congo.
A 12-month study mapping bacterial diversity within a hospital -- with a focus on the flow of microbes between patients, staff and surfaces -- should help hospitals worldwide better understand how to encourage beneficial microbial interactions and decrease potentially harmful contact.